Chinese companies are behind 20% of drugs in development worldwide, showcasing the nation’s growing influence in the pharmaceutical industry. Regulatory and policy reforms in China have propelled its drug development landscape, with the US leading at 40% and the 5EU at 11%. China’s government initiatives aim to boost competitiveness globally.

China’s regulatory reforms, including policies introduced in 2015, have accelerated growth in the pharmaceutical and medtech sectors. The focus on modernizing clinical trials has positioned China as a key player in drug pipelines. Strategic intelligence analyst at GlobalData, Gaffar Aga, commends China’s regulatory advancements in fostering credible innovation.

Strong early-stage drug candidates in China have led to increased licensing deals with Western pharmaceutical companies. AstraZeneca’s $5.2bn partnership with CSPC Pharmaceuticals is a notable example. The NewCo deal structure has gained popularity, shifting towards establishing new companies to handle rights and equity.

Licensing deals between US and Chinese biopharma companies spiked by 280% in 2024. Total transactions among big pharma rose by 66%, indicating China’s appeal as a hub for pipeline discoveries. The country’s role as a global innovator in drug development is reshaping the industry landscape, prompting other markets to stay vigilant.

GlobalData analysts emphasize China’s transition from a ‘me-too’ to a global innovator in drug development. With China accounting for a significant portion of global drug pipelines, other markets must monitor its assets to remain competitive. China’s influence continues to redefine the pharmaceutical landscape on a global scale.

Read more at Yahoo Finance: China accounts for one-fifth of global drugs in development